Know Cancer

or
forgot password

The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases


N/A
55 Years
70 Years
Open (Enrolling by invite only)
Both
Leukemia, Myelodysplastic Syndrome

Thank you

Trial Information

The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases


Inclusion Criteria:



- diagnosed of hematologic malignant disease

- will undergo HLA matced HSCT

- age >=55years

- <55year and intolerable to standard myeloablative conditioning

Exclusion Criteria:

- KPS status <70

- cardiac EF<50%

- creatine clearance <50 ml/min

- ALT more than 10 times of upper normal limit

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

stem cell engraftment

Outcome Time Frame:

30day post transplantation

Safety Issue:

No

Principal Investigator

XiaoJun Huang, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Peking University People's Hospital, Department of Hematology

Authority:

China: Ministry of Health

Study ID:

PKUIH-201303

NCT ID:

NCT01828619

Start Date:

February 2013

Completion Date:

Related Keywords:

  • Leukemia
  • Myelodysplastic Syndrome
  • Hematopoietic Stem Cell Transplantation
  • Busulfan
  • Fludarabine
  • Leukemia
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location